TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24170102
Drug: Tetracosactide (ACTH1‐24)
Normalized name: tetracosactide
DrugBank: Tetracosactide (DB01284)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tetracosactide (ACTH1‐24) therapy
Study: 22186968
Drug: Prehospital loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prehospital loading dose of 600 mg clopidogrel
Study: 22186968
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (clopidogrel administered after diagnostic angiogram)
Study: 22186968
Drug: Prehospital loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prehospital loading dose of 600 mg clopidogrel (treated patients)
Study: 22186968
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (treated patients)
Study: 20107434
Drug: Varenicline 0.5
Normalized name: varenicline 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline 0.5 mg b.i.d.
Study: 22080588
Drug: Varenicline 1
Normalized name: varenicline 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline 1 mg b.i.d.
Study: 20107434
Drug: Varenicline 1
Normalized name: varenicline 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline 1 mg b.i.d. (Male)
Study: 20107434
Drug: Varenicline 1
Normalized name: varenicline 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline 1 mg b.i.d. (Female)
Study: 14551147
Drug: Progestagen-only preparations
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progestagen-only preparations
Study: 11216928
Drug: Second-line protease
Normalized name: protease
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-line protease inhibitor regimen (specific PIs include indinavir and nelfinavir)
Study: 11216928
Drug: Second-line protease
Normalized name: protease
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-line protease inhibitor regimen with added nucleosides
Study: 9522133
Drug: Continuous femoral
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous femoral 3-in-1 block with 0.5% bupivacaine 2 mg kg-1
Study: 8026196
Drug: D‐beta‐hydroxybutyrate infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: D‐beta‐hydroxybutyrate infusion
Study: 2644580
Drug: RS-86 (cholinergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: RS-86 (cholinergic agonist)
Study: 31521496
Drug: Lavage Treatment
Normalized name: Peritoneal Lavage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lavage Treatment (LT) group
Study: 25548861
Drug: 3-week sensory
Normalized name: etonogestrel
DrugBank: Etonogestrel (DB00294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-week sensory cueing treatment
Study: 25548861
Drug: 3-week sham
Normalized name: etonogestrel
DrugBank: Etonogestrel (DB00294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-week sham treatment
Study: 22824168
Drug: L-Carnitine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Carnitine (4 g) for 12 weeks
Study: 18154124
Drug: Cisplatin 6
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 6 mg/m2 intravenously, daily; Radiation therapy: 2 Gy per fraction, 5 times a week, up to 68-70 Gy
Study: 18154124
Drug: Cisplatin 40
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 40 mg/m2, weekly; Radiation therapy: 2 Gy per fraction, 5 times a week, up to 68-70 Gy
Study: 18154124
Drug: Cisplatin 100
Normalized name: CISPLATIN 100MG/VIL (PF) INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin 100 mg/m2, once in 3 weeks; Radiation therapy: 2 Gy per fraction, 5 times a week, up to 68-70 Gy
Study: 15131005
Drug: Angiotensin-converting enzyme
Normalized name: ACE - Angiotensin-converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-converting enzyme (ACE) inhibitor (ramipril)
Study: 15131005
Drug: AT1 antagonist
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: AT1 antagonist (valsartan)
Study: 464673
Drug: 5% dextrose
Normalized name: LMD with 5% Dextrose
DrugBank: D-glucose (DB01914)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% dextrose with an amino acid solution containing 22% BCAAs
Study: 464673
Drug: 5% dextrose
Normalized name: LMD with 5% Dextrose
DrugBank: D-glucose (DB01914)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% dextrose with an amino acid solution containing 35% BCAAs
Study: 464673
Drug: 5% dextrose
Normalized name: LMD with 5% Dextrose
DrugBank: D-glucose (DB01914)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% dextrose with an amino acid solution containing 100% BCAAs
Study: 31075393
Drug: THC (dronabinol;
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC (dronabinol; 5-50 mg, dose individually tailored)
Study: 27402452
Drug: Automated low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automated low glucose insulin suspension system (intervention nights)
Study: 27402452
Drug: Duration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duration of pump suspension
Study: 19770386
Drug: Bortezomib 1.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib 1.3 mg/m(2) twice weekly plus rituximab 375 mg/m(2) weekly for 4 weeks (arm A)
Study: 19770386
Drug: Bortezomib 1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib 1.6 mg/m(2) weekly plus rituximab 375 mg/m(2) weekly for 4 weeks (arm B)
Study: 19770386
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not specified, but implied as single-agent rituximab in ongoing phase III study)
Study: 17803818
Drug: ProAlgaZyme (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: ProAlgaZyme (4 fl oz daily)
Study: 15249319
Drug: Paracetamol 4
Normalized name: Paracetamol 48.2 mg/mL oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 4 g/day (n = 405)
Study: 15249319
Drug: Paracetamol (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (n = 63) in chronic mechanical knee pain subgroup
Study: 10325993
Drug: Hs +
Normalized name: HS-CoM
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hs + Ad group (Hartmann's solution containing 0.5 ml of 1:1000 adrenaline per 500 ml)
Study: 10325993
Drug: Hs group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hs group (Hartmann's solution alone)
Study: 7704169
Drug: Serotype 1
Normalized name: Aspergillus fumigatus serotype 1 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serotype 1 vaccine
Study: 504973
Drug: Subcutaneous heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous heparin (s.c.) injected twice a day
Study: 504973
Drug: Intravenous heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous heparin (i.v.) given by continuous perfusion
Study: 30734016
Drug: Chemotherapy administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy administration
Study: 26062880
Drug: Triple treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple treatment (lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide)
Study: 26062880
Drug: Dual treatment
Normalized name: Meradimate/Octinoxate/Titanium Dioxide Topical application Lotion [PURPOSE DUAL TREATMENT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual treatment (lopinavir-ritonavir plus lamivudine)
Study: 24521629
Drug: Fenofibrate 160
Normalized name: fenofibrate 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate 160 mg/day
Study: 21248328
Drug: Limit feeding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Limit feeding diets containing DDGS at levels of 65 or 55 g/hen per day during the molt period
Study: 17085151
Drug: Aprepitant 160
Normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aprepitant 160 mg once daily for 8 weeks
Study: 2004322
Drug: Postoperative radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative radiation therapy (external irradiation to a dose of 5000 cGy in 5 weeks)
Study: 20969601
Drug: Oral testosterone
Normalized name: testosterone Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral testosterone undecanoate (TU) 200 mg twice daily for 7 days
Study: 20969601
Drug: Oral testosterone
Normalized name: testosterone Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral testosterone undecanoate (TU) 200 mg twice daily for 7 days with finasteride 0.5 mg twice daily
Study: 20969601
Drug: Oral testosterone
Normalized name: testosterone Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral testosterone undecanoate (TU) 200 mg twice daily for 7 days with finasteride 1.0 mg twice daily
Study: 19004202
Drug: Drug group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug group (routine medication)
Study: 19004202
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (including MNEFMSA, affected-channel, and drug)
Study: 8269208
Drug: m7E3 Fab
Normalized name: aDabi-Fab
DrugBank: Idarucizumab (DB09264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: m7E3 Fab (0.15 to 0.35 mg/kg)
Study: 8269208
Drug: Aspirin (325
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (325 mg orally per day)
Study: 3518384
Drug: Hydralazine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydralazine (mean titrated dose 96 +/- 9 mg, mean treatment dose 63 +/- 21 mg administered 3 times daily)
Study: 30200078
Drug: Etanercept 50
Normalized name: etanercept 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 50 mg once weekly (ETN50)
Study: 27441577
Drug: Prophylactic antibiotic
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antibiotic (cefazolin 2 g 30 min before surgery with repetition at 1 g every 3 h during surgery)
Study: 27441577
Drug: No antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotic prophylaxis (Control)
Study: 23087488
Drug: Perphenazine (typical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perphenazine (typical antipsychotic medication)
Study: 23087488
Drug: Newer atypical
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Newer atypical antipsychotics
Study: 15356967
Drug: Calcium Carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium Carbonate (CC)
Study: 12697116
Drug: Shenqi Fuzheng
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenqi Fuzheng injection
Study: 12697116
Drug: Cisplatin-based chemotherapy
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin-based chemotherapy without Shenqi Fuzheng injection
Study: 9162613
Drug: Troglitazone (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone (400 mg day(‐1))
Study: 30093681
Drug: Tamibarotene (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamibarotene (6 mg/m2 daily for 14 days every 3 months for 2 years)
Study: 30093681
Drug: All-trans retinoic
Normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All-trans retinoic acid (ATRA) (45 mg/m2 daily for 14 days every 3 months for 2 years)
Study: 30347030
Drug: L‐CRA plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐CRA plus monthly injections of intravitreal ranibizumab, 0.5 mg (combination group; n = 29)
Study: 30347030
Drug: Ranibizumab alone
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab alone (sham procedure plus monthly injections of intravitreal ranibizumab, 0.5 mg; n = 29)
Study: 27603152
Drug: HOME program
Approvals — FDA: no, EMA: no, PMDA: no
Description: HOME program (enhanced occupational therapy discharge planning intervention with pre- and postdischarge home visits)
Study: 23272061
Drug: Sham injections
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham injections (Control)
Study: 20386343
Drug: Low-dose oral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oral estrogen (1 mg) combined with drospirenone (2 mg) for 2 years
Study: 12645863
Drug: Danazol treatment
Normalized name: Danazol
DrugBank: Danazol (DB01406)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Danazol treatment for 12 weeks
Study: 8621010
Drug: Indomethacin (INDO)
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin (INDO) 50 mg q.i.d.
Study: 31812510
Drug: Belapectin 2
Normalized name: Selamectin
DrugBank: Selamectin (DB11459)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Belapectin 2 mg/kg
Study: 31812510
Drug: Belapectin 8
Normalized name: Selamectin
DrugBank: Selamectin (DB11459)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Belapectin 8 mg/kg
Study: 31812510
Drug: Belapectin 2
Normalized name: Selamectin
DrugBank: Selamectin (DB11459)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Belapectin 2 mg/kg (subgroup without esophageal varices)
Study: 27834984
Drug: Intravenous oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous oxycodone 0.1 mg kg⁻¹
Study: 27834984
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 0.1 mL kg⁻¹
Study: 24747504
Drug: Memantine hydrochloride
Normalized name: Memantine Hydrochloride
DrugBank: Memantine (DB01043)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Memantine hydrochloride (Memary) at a dose of 20 mg/day
Study: 20970380
Drug: High-dose methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methotrexate with whole brain radiotherapy (n=154)
Study: 20970380
Drug: High-dose methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methotrexate without whole brain radiotherapy (n=164)
Study: 20970380
Drug: High-dose methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methotrexate with whole brain radiotherapy
Study: 20970380
Drug: High-dose methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methotrexate without whole brain radiotherapy
Study: 16030104
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of selenium and vitamin E supplementation for 3 to 6 weeks before prostatectomy
Study: 12161049
Drug: Transdermal hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal hormonal replacement therapy system
Study: 12349828
Drug: Ad(GV)CFTR.10 administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad(GV)CFTR.10 administered to airways of individuals with cystic fibrosis (3 x 10(7) to 2 x 10(10) particle units)
Study: 12349828
Drug: Ad(GV)VEGF121.10 administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad(GV)VEGF121.10 administered to myocardium of individuals with coronary artery disease (4 x 10(8) to 4 x 10(10) particle units)
Study: 12349828
Drug: Ad(GV)VEGF121.10 administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad(GV)VEGF121.10 administered to lower extremity muscles of individuals with peripheral vascular disease (4 x 10(8) to 4 x 10(9.5) particle units)
Study: 12349828
Drug: Ad(GV)CD.10 administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad(GV)CD.10 administered to skin of normal individuals (7 x 10(7) to 7 x 10(9) particle units)
Study: 12349828
Drug: Ad(GV)CD.10 administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad(GV)CD.10 administered to airways of normal individuals (7 x 10(8) to 7 x 10(10) particle units)
Study: 12349828
Drug: Ad(GV)CD.10 administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad(GV)CD.10 administered to liver metastasis of individuals with colon carcinoma (4 x 10(8) to 4 x 10(9) particle units)
Study: 12349828
Drug: Control individuals
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control individuals who had chest surgery and bronchoscopy, but no vector administration
Study: 2136974
Drug: Anaritide (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anaritide (all doses except the highest 0.300 microgram/kg/min)
Study: 350491
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg bufexamac
Study: 29436942
Drug: 6‐mm‐long implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6‐mm‐long implants
Study: 29436942
Drug: Normal‐length implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal‐length implants (10 mm)
Study: 26902546
Drug: DTwP vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTwP vaccine first
Study: 26902546
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine first
Study: 18337284
Drug: Amoxicillin 1500
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin 1500 mg QD (or 750 mg if bodyweight ≤30 kg)
Study: 18337284
Drug: Penicillin V
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin V 500 mg BID (or 250 mg if bodyweight ≤20 kg)
Study: 12846450
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human leptin (rL) 10 mg once daily
Study: 12846450
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human leptin (rL) 10 mg twice daily
Study: 9869578
Drug: Three-point models
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-point models developed for the reference formulation
Study: 6130195
Drug: Flubendazole 750
Normalized name: FLUBENDAZOLE
DrugBank: Flubendazole (DB08974)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flubendazole 750 mg intramuscularly once a week for 5 doses
Study: 6130195
Drug: Diethylcarbamazine (DEC)
Normalized name: diethylcarbamazine
DrugBank: Diethylcarbamazine (DB00711)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diethylcarbamazine (DEC) 100 mg twice daily for 14 days
Study: 29917064
Drug: Peficitinib 25
Normalized name: peficitinib
DrugBank: Peficitinib (DB11708)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Peficitinib 25 mg once daily
Study: 29917064
Drug: Peficitinib 75
Normalized name: peficitinib
DrugBank: Peficitinib (DB11708)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Peficitinib 75 mg once daily
Study: 29917064
Drug: Peficitinib 75
Normalized name: peficitinib
DrugBank: Peficitinib (DB11708)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Peficitinib 75 mg twice daily
Study: 29917064
Drug: Combined peficitinib
Normalized name: peficitinib
DrugBank: Peficitinib (DB11708)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Combined peficitinib group (>=75 mg o.d.)
Study: 19014841
Drug: Short-course antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-course antibiotic therapy (7-14 days)
Study: 19014841
Drug: Long-course antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-course antibiotic therapy (14-42 days)
Study: 11812272
Drug: Metered-dose inhaler
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metered-dose inhaler (MDI) formulation of ipratropium bromide
Study: 11812272
Drug: Dry powder
Normalized name: Dry Powder Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry powder inhaler (DPI) formulation of ipratropium bromide
Study: 1897766
Drug: 40 mL
Normalized name: hydrogen peroxide 40 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mL of 0.25% bupivacaine with epinephrine injected intrapleurally postoperatively
Study: 1897766
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL of 0.5% bupivacaine with epinephrine
Study: 30563273
Drug: two servings
Approvals — FDA: no, EMA: no, PMDA: no
Description: two servings of protein (77.2 g, 586 kcal)
Study: 30563273
Drug: two servings
Approvals — FDA: no, EMA: no, PMDA: no
Description: two servings of carbohydrate (126.8 g, 582 kcal)
Study: 30563273
Drug: one serving
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: one serving of protein (38.6 g, 293 kcal)
Study: 30563273
Drug: one serving
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: one serving of carbohydrate (63.4 g, 291 kcal)
Study: 27797709
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein (2 × 28 g/d)
Study: 27797709
Drug: Calcium caseinate
Normalized name: calcium caseinate
DrugBank: Casein (DB10516)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium caseinate (2 × 28 g/d)
Study: 23892826
Drug: Free pharmacotherapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free pharmacotherapy, including nicotine replacement therapy (NRT)
Study: 23892826
Drug: Nominal incentives,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nominal incentives, e.g., gift cards for groceries
Study: 23892826
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment or delayed treatment control groups
Study: 20843217
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of psychosocial skills training, family psycho-education and customary pharmacotherapy
Study: 20843217
Drug: Customary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Customary treatment alone
Study: 12811473
Drug: Milk containing
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk containing 1.8 g of non‐esterified pure plant sterols/d
Study: 10509766
Drug: Uncooked cornstarch
Normalized name: egg shell, cooked
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uncooked cornstarch (0.46 g available CHO/kg body weight)
Study: 10509766
Drug: White bread
Normalized name: White bread
Approvals — FDA: no, EMA: no, PMDA: no
Description: White bread (0.46 g available CHO/kg body weight)
Study: 1718348
Drug: Preoperative intra-arterial
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Preoperative intra-arterial chemotherapy with vincristine and bleomycin for 12 days
Study: 1718348
Drug: Preoperative intra-arterial
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Preoperative intra-arterial chemotherapy
Study: 7039757
Drug: Silicone elastomer
Normalized name: Dover Foley 3-way Silicone Elastomer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicone elastomer intravenous cannula (Visis)